First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Journal Information
Full Title: J Immunother Cancer
Abbreviation: J Immunother Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests: HD, SW, and XY report being employed by Jiangsu Hengrui Pharmaceuticals. The remaining authors declare no other competing interests."
Funding Disclosure
Evidence found in paper:
"Funding: The outstanding discipline leader program from the Science and Technology Commission of Shanghai Municipality (No. 21XD1423200) and National Key Clinical Program on thoracic oncology(2023)"
Protocol Registration
Evidence found in paper:
"Trial registration number NCT04346381."
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025